Dose and schedule as determinants of outcomes in chemotherapy for breast cancer
Author:
Publisher
Elsevier BV
Subject
Oncology,Hematology
Reference63 articles.
1. History of the National Cancer Institute Drug Discovery Program;Sausville,2003
2. Polychemotherapy for early breast cancer;Lancet,1998
3. Tamoxifen for early breast cancer;Lancet,1998
4. Classification of human breast cancer using gene expression profiling as a component of the survival predictor algorithm;Glinsky;Clin Cancer Res,2004
5. Utilizing Nottingham Prognostic Index in microarray gene expression profiling of breast carcinomas;Miller;Mod Pathol,2004
Cited by 14 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Real‐world tolerance and outcomes of oxaliplatin‐based adjuvant chemotherapy for stage III colon cancer—Does dose intensity matter?;Asia-Pacific Journal of Clinical Oncology;2023-05-22
2. HIPEC Methodology and Regimens: The Need for an Expert Consensus;Annals of Surgical Oncology;2021-06-17
3. Patterns of Recurrence after Neoadjuvant Therapy in Early Breast Cancer, according to the Residual Cancer Burden Index and Reductions in Neoadjuvant Treatment Intensity;Cancers;2021-05-20
4. Developing a technology-based intervention for empowering cancer patients from low-income backgrounds: a lifecycle approach;Innovation and Entrepreneurship in Health;2019-05
Developing a technology-based intervention for empowering cancer patients from low-income backgrounds: a lifecycle approach
5. Phase I clinical trial of nintedanib plus paclitaxel in early HER-2-negative breast cancer (CNIO-BR-01-2010/GEICAM-2010-10 study);British Journal of Cancer;2014-07-24
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3